1-3 of 3
Lin Tang
Close
Sort by
Journal Articles

Sgr-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease

Hooman Izadi, Hui Wang, Christian Atsriku, Zef Konst, Adam Levinson, Joseph Piccotti, Steven Pirie-Shepherd, Lin Tang, Dan Weiss, Karen Akinsanya, Hamish Wright, Kristian K Jensen
Journal: Blood
Blood (2023) 142 (Supplement 1): 2801.
https://doi.org/10.1182/blood-2023-181826
Published: 2023
Journal Articles

Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Lyuben Tsvetkov, Janét Pittsenbarger, Christian Atsriku, Paul Devine, Karen Dingley, Adam Levinson, Sayan Mondal, Joseph Piccotti, Roman Shimanovich, Lin Tang, Daniel Weiss, Jacky Woo, Min Ye, Wu Yin, Karen Akinsanya, Wayne Tang, Hamish Wright, Elie Traer, Kristian Jensen
Journal: Blood
Blood (2022) 140 (Supplement 1): 5961–5962.
https://doi.org/10.1182/blood-2022-167239
Published: 2022
Journal Articles

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Lin Tang, PhD, Anna Dolnik, PhD, Kyle J. MacBeth, PhD, Hervé Dombret, Prof., John F. Seymour, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, C.L. Beach, PharmD, Hartmut Döhner, MD, Lars Bullinger, MD
Journal: Blood
Blood (2016) 128 (22): 2859.
https://doi.org/10.1182/blood.V128.22.2859.2859
Published: 2016